Routine Availability of Osimertinib on the NHS
A groundbreaking daily pill that doubles survival time for lung cancer patients, Osimertinib, will now be routinely available on the NHS. This medication, also known as Tagrisso and manufactured by AstraZeneca, has shown significant benefits in preventing cancer recurrence after surgery when used alongside chemotherapy.
Positive Impact and Recommendations
The introduction of Osimertinib through the Cancer Drugs Fund in January 2022 has led to positive outcomes, with trials indicating a substantial increase in disease-free survival time for patients. Notably, those on Osimertinib had a median survival time of 65.8 months compared to 28.1 months for those on a placebo.
Brighter Future for Lung Cancer Patients
With an estimated 600 people in England expected to benefit from this recommendation, the availability of Osimertinib marks a significant advancement in the treatment of lung cancer, a disease responsible for approximately 34,800 deaths annually in the UK.
Patient Testimonials and Medical Insights
Patients like Jules Fielder, who has been taking Osimertinib since 2021, have experienced remarkable results, with her cancer shrinking by 90% within three months of starting the medication. Medical experts emphasize the importance of early detection and advancements in treatment options that offer hope and better outcomes for lung cancer patients.
Accessible and Cost-Effective Treatment
Professor Peter Johnson, NHS England national clinical director for cancer, highlighted the significance of making this life-extending pill available as a cost-effective treatment option for all patients in England with this type of lung cancer. The routine access to cutting-edge treatments like Osimertinib signifies a positive step towards improving outcomes for cancer patients.
